IONSIONIS PHARMACEUTICALS INC
Pharmaceutical Preparations
- Revenue
- $944M
- 34% YoY
- Operating margin
- -40.4%
- 40% YoY
- EBITDA
- −$372M
- 20% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $189M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired14% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $810M | $587M | $788M | $705M | $944M | 34% |
| Operating income | −$30M | −$410M | −$354M | −$475M | −$382M | 20% |
| Net income | −$29M | −$270M | −$366M | −$454M | −$381M | 16% |
| Operating cash flow | $31M | −$274M | −$308M | −$501M | −$269M | 46% |
| Capex | $12M | $16M | $24M | $45M | $51M | 14% |
| Stock-based comp | $121M | $100M | $106M | $130M | $134M | 2.8% |
| Buybacks | $0 | $0 | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $15M · 19
- Net
- −$15M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $13M | $43M | 140 | 125 |
| FY2024 | $15M | −$3M | 58 | 118 |
| FY2023 | $13M | $14M | 84 | 119 |
| FY2022 | $7M | $10M | 63 | 114 |
| FY2021 | $13M | −$3M | 50 | 126 |